These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19794264)

  • 1. KRAS and TP53 mutations in colorectal carcinoma.
    Al-Kuraya KS
    Saudi J Gastroenterol; 2009; 15(4):217-9. PubMed ID: 19794264
    [No Abstract]   [Full Text] [Related]  

  • 2. KRAS mutations in primary and metastatic colorectal cancer.
    Han CB; Li F; Ma JT; Zou HW
    Int J Colorectal Dis; 2013 May; 28(5):731-2. PubMed ID: 22744738
    [No Abstract]   [Full Text] [Related]  

  • 3. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
    Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
    PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
    Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
    Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Consensus for KRAS gene mutation detection in colorectal carcinoma].
    Pathology Quality Control Center of China, Consensus Group for KRAS Gene Mutation Detection in Colorectal Carcinoma
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):635-6. PubMed ID: 23157836
    [No Abstract]   [Full Text] [Related]  

  • 6. The detection of double mutations in KRAS depends on the mutation-detection assay used.
    Hostein I; Lamy A; Faur N; Primois C; Verdon S; Sabourin JC; Soubeyran I
    Clin Chem; 2011 Jul; 57(7):1077-9. PubMed ID: 21441420
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.
    Bass A
    J Clin Oncol; 2011 Jul; 29(19):2728-9. PubMed ID: 21646605
    [No Abstract]   [Full Text] [Related]  

  • 8. Stromal cells do not share KRAS mutations that the epithelial component harbors in colorectal carcinomas.
    Baloglu H; Yigit N
    Cancer Lett; 2011 Sep; 308(1):118-21. PubMed ID: 21624768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel multiple, monoallelic KRAS mutations at codon 12 and 13.
    Keller G; Geist B; Slotta-Huspenina J; Langer R; Nagl F; Fend F; Höfler H; Perren A
    Int J Cancer; 2009 Dec; 125(11):2744-5. PubMed ID: 19521964
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical significance and the handling of KRAS testing on metastatic colorectal cancer].
    Kawamoto Y; Yoshino T
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():346-50. PubMed ID: 22213982
    [No Abstract]   [Full Text] [Related]  

  • 11. KRAS and BRAF mutation status in patients with sporadic colorectal cancer: data from two different Mediterranean countries.
    Symvoulakis EK; Zaravinos A; Zoras O; Spandidos DA
    Int J Biol Markers; 2011; 26(4):276-7. PubMed ID: 22139644
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal small cell carcinoma in ulcerative colitis with identical rare p53 gene mutation to associated adenocarcinoma and dysplasia.
    Hayashi H; Miyagi Y; Sekiyama A; Yoshida S; Nakao S; Okamoto N; Koganei K; Sugita A
    J Crohns Colitis; 2012 Feb; 6(1):112-5. PubMed ID: 22261536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition.
    Rouleau E; Spyratos F; Dieumegard B; Guinebretière JM; Lidereau R; Bièche I
    Br J Cancer; 2008 Dec; 99(12):2100. PubMed ID: 19078954
    [No Abstract]   [Full Text] [Related]  

  • 15. KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics.
    Rechsteiner M; von Teichman A; Rüschoff JH; Fankhauser N; Pestalozzi B; Schraml P; Weber A; Wild P; Zimmermann D; Moch H
    J Mol Diagn; 2013 May; 15(3):299-311. PubMed ID: 23531339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
    Garassino MC; Farina G; Rossi A; Martelli O; Torri V
    J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
    [No Abstract]   [Full Text] [Related]  

  • 17. Genetics: Predictive value of KRAS mutations in chemoresistant CRC.
    Lièvre A; Laurent-Puig P
    Nat Rev Clin Oncol; 2009 Jun; 6(6):306-7. PubMed ID: 19483733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Setting future standards for KRAS testing in colorectal cancer.
    van Krieken H; Tol J
    Pharmacogenomics; 2009 Jan; 10(1):1-3. PubMed ID: 19102707
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysis of circulating tumor DNA to confirm somatic KRAS mutations.
    Holdhoff M; Schmidt K; Donehower R; Diaz LA
    J Natl Cancer Inst; 2009 Sep; 101(18):1284-5. PubMed ID: 19641175
    [No Abstract]   [Full Text] [Related]  

  • 20. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
    Netzel BC; Grebe SK
    Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.